GA attenuates experimental colitis by suppressing IL-6, IL-1β, TNF-α, IL-17 and IFN-γ production and inhibiting p65-NF-κB and IL-6/p-STAT3 (Y705) activation [40]. Here, IL17A is linked to colitis.